The mechanisms underlying neointima formation remain unclear. Interferon regulatory factors (IRFs), which are key innate immune regulators, play important roles in cardiometabolic diseases. However, the function of IRF4 in arterial restenosis is unknown.
C ardiovascular diseases are the most common causes of death in developed societies, and atherogenesis is the leading pathophysiological cause of cardiovascular diseases.
1,2 Surgical procedures, including angioplasty, stenting, atherectomy, and bypass surgery, remain indispensable treatments for patients with life-threatening coronary atherosclerosis; however, restenosis after mechanical injuries is the most prominent pathological issue limiting the prognoses of these patients. 3 It is well known that the hallmark of restenosis is arterial neointima formation, during which vascular smooth muscle cells (SMCs) dedifferentiate, proliferate, migrate, and secrete more extracellular matrix in response to stimuli. 4 However, treatments for restenosis remain far from satisfactory, mainly because of a lack of a clear understanding of the molecular mechanisms underlying restenosis development.
Innate immune signaling networks can affect the progression of cardiovascular diseases by functioning in nonimmune cells. 5 Interferon regulatory factors (IRFs), which were originally identified as transcriptional regulators of type I interferon, are key regulators of innate immune signaling. 6 Some IRFs have also been found to play important roles in insulin resistance, [7] [8] [9] heart disease, [10] [11] [12] [13] [14] [15] [16] [17] cell survival, 18, 19 oncogenesis, 6, 20 and neointima formation. [21] [22] [23] [24] [25] IRF4, the fourth member of the IRF family, was initially identified in B and T lymphocytes, in which it regulates host cell differentiation. 6 Similar to other members of its family, IRF4 harbors a highly conserved DNA-binding domain in its N-terminal and an IRF-association domain in its C-terminal. 26 Under certain circumstances, IRF4 can regulate the transcriptional activity of its target genes by binding to interferon-stimulating response elements (ISREs) via its DNA-binding domain after interacting with cofactors via its IRF-association domain. 26 Most previous studies have shown that IRF4 plays a critical role in regulating the differentiation of lymphoid, myeloid, and dendritic cells 6 ; however, its tumor-suppressing functions have also been addressed. 27, 28 Moreover, IRF4 acts as a protective regulator against metabolic diseases by regulating macrophage polarization 29 and as a transcriptional driver of thermogenic gene expression and energy expenditure by interacting with peroxisome proliferator-activated receptor-γ coactivator 1α. 30 We recently found that IRF4 overexpression aggravates cardiac hypertrophy by promoting the transcriptional regulation of cAMP response element binding protein 11 but protects against ischemic stroke by enhancing the expression of serum response factor. 19 These results indicate that IRF4 can play very different roles by regulating different downstream molecular signaling in nonimmune cells under different pathophysiological conditions. Therefore, it is very intriguing to explore whether and how the key regulator of innate immunity IRF4 functions in neointima formation because understanding this issue is also critical for understanding the mechanisms underlying restenosis.
In this study, we demonstrated that IRF4 protects arteries against neointima formation. In terms of the mechanism underlying this effect, we found that IRF4 promotes the expression of Krüppel-like factor 4 (KLF4) by directly binding to its promoter. Consistent with this finding, we found that KLF4 overexpression compensated for the neointima formation-promoting effects of IRF4 ablation, whereas KLF4 ablation abolished the neointima formation-inhibiting effects of IRF4 overexpression. These observations indicate that the protective effects of IRF4 against neointima formation are KLF4-dependent. Our findings suggest that this previously undiscovered IRF4-KLF4 axis plays a role in vasculoproliferative pathology and may thus be a promising therapeutic target for the treatment of arterial restenosis.
Clinical Perspective
What Is New?
• We found that the key innate immune transcriptional regulator interferon regulatory factor 4 (IRF4) presented in the smooth muscle cells (SMCs) functions to inhibit the neointima formation after arterial injury by preventing the proliferation of the SMCs.
• IRF4 promotes Krüppel-like factor 4 (KLF4) expression by directly binding to its promoter during neointima formation.
• Genetic overexpression of KLF4 in SMCs largely reversed the neointima-promoting effect of IRF4 ablation, whereas ablation of KLF4 abolished the protective function of IRF4, indicating that the protective effects of IRF4 against neointima formation are KLF4-dependent.
• IRF4 promoted SMC dedifferentiation.
What Are the Clinical Implications?
• Despite the improvement of arterial expansion procedures for patients with life-threatening coronary atherosclerosis, restenosis remains the most prominent pathological issue and limits the curative effect.
• Development of new strategies to solve this problem is hindered by the lack of a full understanding of the mechanism underlying the pathogenesis. • IRF4 acts as a novel regulator of arterial restenosis that functions in the proliferation and migration of vascular SMCs.
• The newly discovered IRF4-KLF4 axis may be a promising target for developing therapeutic strategies against arterial restenosis.
METHODS
For detailed information on the materials and methods, see Materials and Methods in the online-only Data Supplement.
Animals and Treatment
The animal study protocols were approved by the Animal Care and Use Committee of Renmin Hospital at Wuhan University, China. Global IRF4-deficient mice (IRF4-knockout [KO], C57BL/6J background) were generated with the CRISPR (clustered regularly interspaced short palindromic repeats)/ Cas9 system as previously described. 31 IRF4-deficient rats were generated with the TALEN technique (Transcription ActivatorLike Effector Nuclease). SMC-specific IRF4-KO (SMC-IRF4-KO) mice were produced by crossing IRF4 flox/flox /SM22α-Cre mice. SMC-specific IRF4-transgenic (TG) (SMC-IRF4-TG) mice were generated by microinjecting the SM22α-IRF4 construct into fertilized mouse embryos (C57BL/6J background). To generate SMC-specific KLF4-TG mice, we ligated full-length mouse KLF4 cDNA into a vector containing a mouse SM22α promoter, a 5ʹ-HA tag, and an SV40 polyA signal and subsequently microinjected the construct into fertilized mouse embryos (C57BL/6J background). SMC-IRF4-KO/KLF4-TG mice were generated by breeding IRF4 flox/flox /SM22α-Cre mice with SMC-specific KLF4-TG mice. KLF4 flox/flox mice were constructed with the CRISPR/Cas9 system. SMC-specific KLF4-KO mice were created by crossing KLF4 flox/ flox mice with SM22α-Cre mice to generate KLF4 flox/flox /SM22α-Cre mice. SMC-IRF4-TG/KLF4-KO mice were generated by breeding SMC-specific KLF4-KO mice with SMC-IRF4-TG mice. Male mice (10-12 wk old, 25-30 g) were used and maintained in temperature-and humidity-controlled rooms under a 12/12-hour light/dark cycle. Food and water were available ad libitum. For detailed information, see Materials and Methods in the online-only Data Supplement.
Human Samples
All procedures involving human samples complied with the principles outlined in the Declaration of Helsinki and were approved by the Institutional Review Board of Renmin Hospital of Wuhan University, China. The human ethics approval number is 2014-K-016. Informed consent was obtained from each participating patient. The control coronary artery samples were obtained from normal heart donors who had undergone heart surgery but were not suitable for transplantation, and the in-stent restenotic arteries were collected from the coronary arteries of patients with coronary heart disease undergoing heart transplantations who had ever received percutaneous coronary intervention. For detailed information, see Materials and Methods in the online-only Data Supplement.
Carotid Artery Wire Injury Model
Neointima formation in the mouse carotid artery was induced by wire injury as previously described. 23 Sham control mice underwent the same procedure but were not subjected to vascular injury. For detailed information, see Materials and Methods in the online-only Data Supplement.
Rat Carotid Artery Balloon Injury Model
The carotid artery balloon injury model was induced in male Sprague-Dawley rats (300 g) as previously described. 32 For detailed information, see Materials and Methods in the online-only Data Supplement.
Histological and Morphometric Analyses
The mice were euthanized via overdoses of sodium pentobarbital (150 mg/kg) at 0, 7, 14, or 28 days after injury. The carotid arteries were excised after circulation perfusion, fixed with 4% paraformaldehyde in PBS, and preserved for further embedding, sectioning, histological staining, and analyses, as previously described. 21 For morphometric analysis, hematoxylin and eosin or Elastica van Gieson staining was performed to define the vascular tissue structures and the extent of carotid artery luminal occlusion. The resulting amount of neointima formation (intimal area and the intima-to-media ratio) was determined by a single observer who was blinded to the treatment protocols using Image-Pro Plus 6.0 (Media Cybernetics, Rockville, MD). For detailed information, see Materials and Methods in the online-only Data Supplement.
Immunofluorescence Staining
Immunofluorescence staining was performed as previously described, 21 and the images were captured with a confocal laser scanning microscope. All antibodies are listed in Table I in the online-only Data Supplement. For detailed information, see Materials and Methods in the online-only Data Supplement.
Cell Culture and Adenovirus Infection
The mouse SMC line mouse aorta vascular SMC (MOVAS) was acquired from the American Type Culture Collection. The primary vascular SMCs (VSMCs) were isolated at the indicated time from the injured or control carotid arteries of male C57BL/6J mice via enzymatic digestion. AdIRF4 and AdshIRF4 were generated as previously described, 19 and AdshRNA was used as a nontargeting control. The MOVASs were infected with recombinant adenoviruses at a multiplicity of infection of 25 particles per cell for 24 hours. For detailed information, see Materials and Methods in the online-only Data Supplement.
Quantitative real-time polymerase chain reaction (qPCR) and Western blotting were performed with the material isolated from the indicated tissues or cells, as previously described. 19 All antibodies and primers used for real-time polymerase chain reaction are listed in Tables II and III 
Gelatin Zymography
Protein lysates (15 mg) from the mouse carotid arteries (sham operation and 28-day postinjury groups) were electrophoresed on 10% SDS-PAGE gels containing 1% gelatin for the detection of gelatinase activity. After electrophoresis, the gels were washed with 2.5% Triton X-100 and incubated overnight in buffer containing the indicated compounds (10 mmol/L CaCl 2 , 0.01% NaN 3 , and 50 mmol/L Tris-HCl, pH 7.5). The gels were subsequently stained with 0.2% Coomassie Brilliant Blue for 2 hours before being destained with 10% acetic acid and 40% methanol. For detailed information, see Materials and Methods in the online-only Data Supplement.
Luciferase Reporter Assays
The luciferase reporter plasmid pGL3-pmKLF4 was generated by amplifying the klf4 promoter from the C57BL/6 genome (NC_000076.6) and ligating it into the pGL3-basic vector (Promega, Madison). The IRF4 binding sites in the klf4 promoter were predicted by bioinformatics analyses. The ISRE core sequence deletion plasmid pGL3-pmKFL4-del was generated by the fusion-polymerase chain reaction approach. The MOVASs were cotransfected with 100 ng pGL3-pmKFL4 or pGL3-pmKFL4-del and 1 ng pRL-TK-Luc. After 4 hours, the cells were treated with PDGF-BB (20 ng/mL) for 24 hours, harvested, and lysed with 100 μL passive lysis buffer (Promega). After removing the cell debris, we detected the supernatant with a SingleMode SpectraMax Microplate Reader, in accordance with the manufacturer's instructions. For detailed information, see Materials and Methods in the online-only Data Supplement.
Chromatin Immunoprecipitation
MOVASs were treated with PDGF-BB (20 ng/mL) for 24 hours, harvested, fixed with 1% formaldehyde in PBS for 10 minutes, and washed with ice-cold PBS. The cells were then sonicated, immunoprecipitated with goat anti-IRF4 (Santa Cruz, sc-6059x) or normal goat immunoglobulin G (Santa Cruz, sc2028), and enriched with protein A-and protein G-coupled magnetic beads. The precipitated DNA was subsequently extracted and detected via qPCR using the corresponding primer pairs. For detailed information, see Materials and Methods in the online-only Data Supplement.
Microarray Performance and Analysis
Total RNA from the carotid arteries of wild-type (WT; n=3) and IRF4-KO (n=3) mice at 14 days after vascular injury was extracted and used for microarray analysis with the Mouse Genome 430 2.0 Array (Affymetrix). The microarray data have been stored in and are available through the National Center for Biotechnology Information Gene Expression Omnibus (series accession No. GSE88930). The normalized expression of differentially expressed genes was used to generate the heat map, in which red indicates positive correlation and green indicates negative correlation. For detailed information, see Materials and Methods in the online-only Data Supplement.
Statistical Analysis
All data were presented as the mean±SD. Parametric statistical analysis between 2 groups was done with 2-tailed Student t tests. A 1-way ANOVA was used for comparisons among >2 groups followed by a Bonferroni post hoc test or the Tamhane T2 post hoc test. Nonparametric statistical analysis between 2 groups was performed by the Mann-Whitney test, whereas the Kruskal-Wallis test followed by the Dunn test was used for multiple comparisons. A value of P<0.05 was considered to be statistically significant. All statistical analyses were performed with SPSS software (version 19.0, SPSS Inc, Chicago, IL). For detailed information, see Materials and Methods in the online-only Data Supplement.
RESULTS

IRF4 Is Closely Associated With Arterial Injury
We first compared the expression levels of IRF4 in human coronary arteries with restenosis with those in coronary arteries without restenosis and found that IRF4 was expressed at significantly lower levels at both the mRNA ( Figure 1A ) and protein ( Figure 1B ) levels in arteries with restenosis than in coronary arteries without restenosis. Using the mouse carotid artery injury model ( Figure I in the online-only Data Supplement), we found that IRF4 expression levels changed in response to injury in a time-dependent manner because IRF4 expression levels were markedly increased at both the mRNA and protein levels at 7 and 14 days after injury but were significantly decreased at both the mRNA ( Figure 1C ) and protein ( Figure 1D ) levels at 28 days after injury. Furthermore, we compared the expression pattern of IRF4 with that of IRF3 and IRF9 in restenosis. The last 2 IRFs have been demonstrated to play important roles in neointima formation. 21, 23 The results indicated that IRF4 expression showed a similar change with IRF3, whereas IRF9 expression was increased in both mouse and hu- . The response of IRF4 expression to arterial injury suggested that IRF4 may play an important role in restenosis development and neointima formation. To confirm this possibility, we performed a carotid artery injury procedure on IRF4-KO mice ( Figure III in the online-only Data Supplement) and found that universal IRF4 ablation accelerated neointima formation after injury ( Figure 1E ). The neointima in the IRF4-KO group was significantly thicker than that in the WT group (Figure 1F) , and an increased intima-to-media ratio (Figure 1G ) was observed in the arteries of IRF4-KO mice compared with the arteries of WT mice at 7, 14, and 28 days after injury. The above-mentioned difference was observed as early as 7 days after injury induction and persisted for at least 28 days ( Figure 1E-1G ). To determine the effects of IRF4 on arterial injury in other species, we knocked out IRF4 in rats using the TALEN technique. We synthesized a pair of TALENs designed to interrupt the rat IRF4 gene at the third exon ( Figure 1H ). The targeting construct was tested via digestion assay ( Figure 1I ), and IRF4 gene interruption was verified by sequencing the cloned polymerase chain reaction products from WT and founder rats. The immunoblots demonstrated deficient IRF4 expression in the aorta of IRF4-KO rats ( Figure 1J ). After balloon injury, IRF4-KO rats exhibited more abundant neointima in their injured carotid arteries than their WT littermates as demonstrated via Elastica van Gieson staining of carotid artery sections at 7 and 14 days after injury ( Figure 1K ). These results indicate that IRF4 is closely associated with arterial injury and that the absence of IRF4 substantially promotes neointima formation after arterial injury.
SMCs Express IRF4 During Neointima Formation
Given the central roles played by SMCs in atherosclerosis and vascular remodeling 33 and the above-aforementioned findings concerning the involvement of IRF4 in neointima formation, we investigated whether IRF4 is expressed by SMCs in neointimal lesions. Immunostaining of human coronary artery specimens indicated that SMCs expressed IRF4 in both normal and restenotic human coronary arteries ( Figure 2A and Figure IVA in the online-only Data Supplement). IRF4 expression levels were lower in restenotic human coronary arteries than in normal human coronary arteries, a result consistent with those mentioned above ( Figure 2B ). To examine IRF4 expression in macrophages, we costained human specimens for Mac3 (a macrophages marker) and IRF4. We observed a downregulated IRF4 expression in restenotic coronary arteries, and a small portion of IRF4 was located in macrophages ( Figure VA in the onlineonly Data Supplement). In injury-induced hyperplastic mouse carotid arteries, immunofluorescence staining revealed that all SMCs, which were identified via staining for α-smooth muscle actin (α-SMA) and SM22α, were positive for IRF4 expression ( Figure 2C and Figure IVB in the online-only Data Supplement). Consistent with the Western blotting results pertaining to the injured carotid arteries, the results of this experiment showed that the abundance of IRF4 (as demonstrated by the optical density of immunofluorescence staining for IRF4) was markedly increased at 7 days after injury and was further increased at 14 days after injury; however, the abundance of IRF4 was dramatically decreased at 28 days after injury, which was after the acute postinjury phase had ended ( Figure 2C ). IRF4 levels were higher in the neointima of SMCs than in the media of SMCs at 7, 14, and 28 days after injury (Figure 2D ). Next, we costained IRF4 with Mac3 to examine IRF4 expression in the macrophages of mice and found IRF4 expression in the macrophages (Figure VB in the online-only Data Supplement). Western blot analysis of the proteins extracted from SMCs isolated from the control carotid arteries and injured carotid arteries at different time points revealed that IRF4 expression levels were increased after wire injury (on days 7 and 14) but decreased after the acute phase in injured carotid arteries compared with control carotid arteries (on day 28; Figure 2E and 2F). We also observed that IRF4 ex- Figure 1 Continued. to GAPDH levels. n=4. *P<0.05 vs normal group. C, Relative IRF4 mRNA expression in wild-type (WT) mice at various time points after injury. n=3 samples per group at each time point. *P<0.05 vs sham group. #P<0.05 vs the 7-day injury group. †P<0.05 vs the 14-day injury group. D, Changes in IRF4 expression as determined by Western blotting at the indicated times. n=3 samples per group at each time point. *P<0.05 vs sham group. #P<0.05 vs the 7-day injury group. †P<0.05 vs the 14-day injury group. E through G, Elastica van Gieson (EVG)-stained sections demonstrating the intimal areas in WT and IRF4-knockout (KO) mice at the indicated times. Scale bar=50 μm. Right, Quantified intimal area and the intimato-media (I/M) ratio (n=6-9 at 7 days, n=6 at 14 days, n=6 at 28 days). *P<0.05 vs the WT group. H, Schematic representation demonstrating the TALEN (Transcription Activator-Like Effector Nuclease) target site in exon 3 of the rat IRF4 gene. DNA sequences of the cloned polymerase chain reaction products from WT and founder rats. I, Agarose gel of a T7E1 digestion assay demonstrating digestion products of the predicted size from mutant (530 bp) and Sprague-Dawley (SD) rats (340 and 190 bp). Arrows indicate the sizes of the bands. J, Immunoblots demonstrating IRF4 expression in SD and IRF4-deficient rats. K, Representative histological sections of EVG-stained rat carotid arteries from IRF4-KO rats at 7 and 14 days after balloon injury. Scale bar=100 μm. Right, Quantification of the intimal area (top) and the I/M ratio at the indicated times (bottom; n=6-7 at each time point). *P<0.05 vs the control group. Data are expressed as mean±SD. Statistical comparisons were performed by 2-tailed Student t tests (A, B, F, G, and K) or 1-way ANOVA with the Tamhane T2 posttest (C and D).
pression levels were increased in human aortic VSMCs after PDGF-BB treatment from 0 to 24 hours but decreased at 48 hours (Figure VI in the online-only Data Supplement). These results indicate that restenosis deterioration in global IRF4-KO animals may be attributable to the absence of IRF4 from SMCs.
SMC-Specific IRF4 Ablation Promoted Neointima Formation
We constructed SMC-IRF4-KO mice to verify the role of IRF4 in neointima formation. Western blot analysis showed that IRF4 expression levels were significantly decreased in the carotid arteries of SMC-IRF4-KO mice compared with control mice (Figure 3A) , which was verified by immunostaining ( Figure 3B ). The SMC-IRF4-KO did not affect the metabolic parameters, body weight, and inflammatory cytokines (Figure VII in the online-only Data Supplement). SMC-IRF4-KO mice exhibited more severe neointima formation than their SMC-Cre littermates when lesion sizes were measured at 14 and 28 days after carotid artery wire injury (Figure 3C) , and the effect was not related to blood pressure and cardiac function (Figure VIII in the online-only Data Supplement). Immunofluorescence staining (Figure 3D) and Western blot analyses ( Figure 3E ) revealed that the expression levels of the proliferation suppressor P21 were downregulated, but the levels of the proliferation-inducing genes CyclinD1 and proliferating cell nuclear antigen (PCNA) were upregulated in SMC-IRF4-KO mice compared with SMC-Cre control mice at 14 and 28 days after injury. In primary SMCs, the absence of IRF4 significantly promoted PDGF-BB-induced BrdU incorporation ( Figure 3F ). When subjected to PDGF-BB stimulation, SMC-Cre mouse SMCs initially displayed increased IRF4 transcript levels after 24 hours, followed by decreased IRF4 transcript levels after 48 hours (Figure 3G ). This alteration in IRF4 expression was similar to that observed in mouse carotid arteries after wire injury. qPCR revealed that P21 transcript levels were downregulated but CyclinD1 and PCNA transcript levels were upregulated in SMC-IRF4-KO mouse SMCs compared with SMC-Cre mouse SMCs at 24 and 48 hours after PDGF-BB stimulation ( Figure 3G ).
Matrix metalloproteinase (MMP)-facilitated SMC migration from the media to the intima is critical for postinjury neointima formation. 6 Our Western blotting results revealed that IRF4 ablation in SMCs promoted injury-induced upregulation of MMP2 but not MMP9; however, the absence of IRF4 did not change the MMP2 or MMP9 expression levels in the sham group ( Figure 3H) . The promoting effects of IRF4 ablation on MMP2 expression were also verified via immunostaining of carotid artery tissue sections collected from SMC-IRF4-KO and SMC-Cre mice at 14 and 28 days after injury ( Figure 3I ). Consistent with these results, the gelatin zymography results revealed that MMP2 activity was also promoted by IRF4 ablation in injured carotid arteries ( Figure 3J ). Transwell migration assays demonstrated that IRF4-ablated mouse SMCs exhibited stronger migration ability than SMC-Cre mouse SMCs after induction with PDGF-BB ( Figure 3K ). Collectively, these data suggest that IRF4 plays a protective role in SMCs during restenosis.
SMC-Specific IRF4 Overexpression Inhibited Neointima Formation
We subsequently generated SMC-IRF4-TG mice using TG constructs containing mouse IRF4 cDNA under the control of an SMC-specific mouse minimal SM22α promoter ( Figure 4A ) to confirm the protective role of IRF4 in restenosis. We found that IRF4 expression levels in the arteries of the 4 SMC-IRF4-TG mouse lines were 2.0-fold (TG1), 2.6-fold (TG2), 3.6-fold (TG3), and 1.9-fold (TG4) fold higher than those in the arteries of WT mice ( Figure IXA in the online-only Data Supplement). We therefore selected the TG3 line for subsequent experiments. Elastica van Gieson staining demonstrated that the neointimal area and the intima-to-media ratio were significantly decreased in the carotid arteries of SMC-IRF4-TG mice compared with the carotid arteries of nontransgenic (WT) mice at 14 and 28 days after arterial injury ( Figure 4B ). Similarly, both TG1 and TG2 mice exhibited a thinner neointima than their WT littermates at 14 days after wire injury induction ( Figure  IXB in the online-only Data Supplement). In contrast to SMC-IRF4-KO mice, SMC-IRF4-TG mice displayed decreased PCNA and CyclinD1 expression levels, and Figure 3 Continued. SMC-IRF4-KO mice at 14 and 28 days after injury. The proportions of PCNA-positive cells and the integral optical density (IOD) values of CyclinD1 and P21 immunostaining were calculated (n=5-7 at 14 days, n=5-6 at 28 days). Scale bar=50 μm. E, Western blot analysis (left) and quantification (right) of P21, PCNA, and CyclinD1 protein levels in the arteries of SMC-Cre and SMC-IRF4-KO mice after sham surgery or at 28 days after injury. n=3 samples per group for each time point; 3 to 4 carotid arteries were collected as 1 sample. F, Primary mouse SMCs isolated from SMC-Cre and SMC-IRF4-KO mice were harvested and used for the BrdU incorporation assays, which were performed at an absorbance at 370 nm to assess SMC proliferation on platelet-derived growth factor-BB (PDGF-BB) stimulation. n=6 per group. G, mRNA expression levels of IRF4, P21, PCNA, and CyclinD1 in primary SMCs from SMC-Cre and SMC-IRF4-KO mice before or after 24 or 48 hours of PDGF-BB stimulation. n=3 per group. H, Western blot analysis (left) and quantification (right) of matrix metalloproteinase (MMP)-2 and MMP9 protein levels in the arteries of SMC-Cre and SMC-IRF4-KO mice after sham surgery or at 28 days after injury. n=3. I, Immunofluorescence staining demonstrating MMP2 (red) expression in both the neointima and media of SMC-Cre and SMC-IRF4-KO mice at 14 and 28 days after injury. IOD values for MMP2 immunostaining were calculated (n=5-7 at 14 days, n=5-6 at 28 days). Scale bar=50 μm. J, Gelatin zymography was performed to examine MMP2 activity in fresh carotid artery specimens from SMC-Cre and SMC-IRF4-KO mice after sham operation or at 28 days after injury. β-Actin served as the loading control. n=3. K, Primary mouse SMCs from SMC-Cre and SMC-IRF4-KO mice were seeded on Transwell dishes, exposed to PBS or PDGF-BB for 6 hours, and then subjected to Transwell migration assay. n=6 samples per group. *P<0.05 vs the SMC-Cre group. Data are expressed as mean±SD. Statistical comparisons were performed by Mann-Whitney test (A) or 2-tailed Student t tests (C-K). P21 expression levels in these mice were increased compared with those in WT control mice, as demonstrated via immunostaining of the carotid artery sections at 14 and 28 days after injury ( Figure 4C ). The increase in P21 expression and decreases in PCNA and CyclinD1 expression were verified by Western blot at 28 days after injury ( Figure 4D ). qPCR analysis demonstrated that SMC-specific overexpression inhibited PCNA and CyclinD1 transcription but promoted P21 transcription ( Figure 4E) . In primary SMCs, IRF4 overexpression decreased PDGF-BB-induced BrdU incorporation (Figure 4F) . In addition, injury-induced MMP2 expression and MMP2 activity were suppressed in SMC-IRF4-TG mouse arteries ( Figure 4G and 4H) . Transwell SMC migration was also inhibited by IRF4 overexpression (Figure 4I) . These findings confirm that IRF4 overexpression specifically in SMCs is sufficient for protecting arteries against restenosis.
IRF4 Directly Promotes KLF4 Expression in SMCs
To investigate the mechanism underlying the effects of IRF4 on restenosis, we performed a genome-wide microarray screen and ingenuity pathway analyses. The results revealed that the mRNA expression levels of genes related to proliferation (CyclinD1 and PCNA), migration (MMP2), SMC differentiation (α-SMA, SM22α and Smoothelin), and inflammation development (tumor necrosis factor-α, inducible nitric oxide synthase, and interleukin-6) were significantly increased but the mRNA expression levels of genes reported to inhibit proliferation (P21, KLF4) and inflammation (Retnla, Arg-1, peroxisome proliferator-activated receptor-γ, and Chi3l3) were decreased in the carotid arteries of IRF4-deficient mice compared with control mice at 14 days after injury ( Figure 5A and Figure X in the onlineonly Data Supplement). These alterations were verified by qPCR analysis (Figure 5B ), indicating elevated inflammation in the IRF4-deficient mice, in agreement with the accelerated neointima formation. Among the above genes, KLF4 is known to play key roles in SMC phenotype modulation and neointima formation. 34, 35 Immunofluorescence staining for KLF4 and α-SMA in the neointima of SMC-Cre and SMC-IRF4-KO mice after sham surgery and at 28 days after injury indicated that KLF4 expression in SMCs was induced by vascular injury but downregulated by SMC-specific IRF4 ablation ( Figure 5C ), whereas KLF4 expression in SMCs was upregulated by SMC-specific IRF4 overexpression ( Figure  XI in the online-only Data Supplement). qPCR analysis verified that IRF4 ablation significantly inhibited injuryinduced KLF4 upregulation; however, qPCR analysis also demonstrated that SMC-specific IRF4 overexpression enhanced injury-induced KLF4 upregulation (Figure 5D ). In the postinjury carotid arteries at 28 days, we also observed that KLF4 protein expression levels were decreased by SMC-IRF4-KO but were increased as a result of SMC-specific IRF4 overexpression ( Figure 5E ). These results indicate that IRF4 promotes KLF4 expression at the transcriptional level in SMCs.
Previous chromatin immunoprecipitation-sequencing analysis of IRF4 suggests a directive regulation of KLF4 expression by IRF4 [36] [37] [38] [39] [40] in T cells and B cells. We performed bioinformatics analysis and identified 6 putative ISREs in the KLF4 gene promoter ( Figure 5F ). Chromatin immunoprecipitation assays demonstrated that P3 (−1544 to ≈−1435) and P4 (−1003 to ≈−910) were the 2 significant ISREs that allowed IRF4 to bind to the KLF4 gene, whereas mIL12-pro84 served as a positive control, and GAPDH served as a nonspecific control ( Figure 5F ).In primary SMCs, PDGF-BB treatment enhanced KLF4 transcriptional activity (as demonstrated via KLF4-luc luciferase reporter assays), which was decreased by IRF4 ablation but increased by IRF4 overexpression ( Figure 5G ). In MOVASs, KLF4 transcriptional activity was enhanced by adenovirus-mediated IRF4 overexpression. Mutating the IRF4-binding sites in the ISREs of the KLF4 promoter blunted these IRF4-specific effects ( Figure 5H ), indicating that IRF4 promotes KLF4 Figure 4 Continued. IRF4-TG (SMC-IRF4-TG) mice at 14 or 28 days after wire injury. Bottom, The quantified intimal areas and intima-to-media ratios (n=6-8 at 14 days, n=6 at 28 days). Scale bar=50 μm. C, Proliferating cell nuclear antigen (PCNA), CyclinD1, and P21 (red) expression levels in both the neointima and media of WT and SMC-IRF4-TG mice at 14 and 28 days after injury as demonstrated by immunofluorescence staining. The proportions of PCNA-positive cells and the integral optical density (IOD) values for CyclinD1 and P21 immunostaining were calculated (n=6-9 at 14 days, n=4-6 at 28 days). Scale bar=50 μm. D, Western blot analysis (left) and quantification (right) of P21, PCNA, and CyclinD1 protein levels in the arteries of WT and SMC-IRF4-TG mice after sham surgery or at 28 days after injury. n=3. E, IRF4, P21, PCNA, and CyclinD1 mRNA expression levels in the carotid arteries of WT and SMC-IRF4-TG mice after sham surgery or at 28 days after injury. n=3 per group. F, WT and SMC-IRF4-TG primary mouse SMC proliferation as determined via BrdU incorporation assays after plateletderived growth factor-BB (PDGF-BB) stimulation. n=6 per group. G, Immunofluorescence staining demonstrating matrix metalloproteinase-2 (MMP2; red) expression in both the neointima and media of WT and SMC-IRF4-TG mice at 14 and 28 days after injury. The IOD values for MMP2 immunostaining were quantified (n=6 at 14 days, n=5-6 at 28 days). Scale bar=50 μm. H, Gelatin zymography was performed to examine MMP2 activity in fresh carotid artery specimens from WT and SMC-IRF4-TG mice after sham operation or at 28 days after injury. β-Actin served as the loading control. n=3. I, Migration of primary SMCs from WT and SMC-IRF4-TG mice in Transwell dishes after PBS or PDGF-BB stimulation. n=6 samples per group. *P<0.05 vs the WT group. Data are expressed as mean±SD. Statistical comparisons were performed by 2-tailed Student t tests. 
The Effects of IRF4 on Neointima Formation Are Mediated by KLF4
We investigated whether the effects of IRF4 on neointima formation are mediated by KLF4 in vivo. Therefore, we first crossed IRF4 flox/flox /SM22α-Cre + mice (generated by crossing IRF4 flox/flox mice with SM22α-Cre mice) with CAG-KLF4 + mice to generate SMC-IRF4-KO/KLF4-TG mice ( Figure 6A ). The absence of IRF4 expression and increases in KLF4 expression in the aortas of SMC-IRF4-KO/KLF4-TG mice were confirmed by Western blotting ( Figure 6B ). We also generated SMC-IRF4-TG/KLF4-KO mice ( Figure 6C ). SMC-specific KLF4-KO mice were generated by crossing KLF4 flox/flox mice with SM22α-Cre mice. LoxP knockin was performed with the CRISPR/ Cas9 technique ( Figure XIV in the online-only Data Supplement). All of these mice and their corresponding control mice were subjected to carotid artery wire injury surgery. Twenty-eight days after injury, SMC-IRF4-KO/KLF4-TG mice exhibited significantly smaller intimal areas and lower intima-to-media ratios than SMC-IRF4-KO mice, thus indicating that KLF4 overexpression ameliorated IRF4 ablation-potentiated neointima formation ( Figure 6D) . Consistent with the findings about alterations in the intima, the findings pertaining to this experiment showed that TG overexpression of KLF4 specifically in SMCs also reversed the above-mentioned increases in PCNA, MMP2, and α-SMA expression levels and simultaneously decreased P21 expression levels ( Figure 6E ). In SMC-IRF4-TG/KLF4-KO mice, SMC-specific KO of KLF4 completely abolished the protective effects of SMC-IRF4-TG against wire injury-induced neointima formation ( Figure 6F ); these changes were accompanied by increases in PCNA, MMP2, and α-SMA expression and a decrease in P21 expression in the indicated mice compared with SMC-IRF4-TG mice ( Figure 6G ). These results verified that IRF4 functions in neointima formation by modulating KLF4 expression and confirmed that KLF4 protects against arterial injury in an inducible KLF4-KO mouse model. 35 
The Effect of IRF4 on Phenotypic Switching of SMCs
In addition to proliferation, SMC phenotypic switching is critical for neointima formation in response to vascular injury, in which KLF4 plays a key role. 34, 35 Therefore, we next examined whether deletion of the IRF4 gene affects Figure 5 Continued. (WT) group. C, Immunofluorescence staining for KLF4 (red) and α-smooth muscle actin (α-SMA; green) was performed to determine KLF4 expression and localization in both the neointima and media of SMC-Cre and SMC-IRF4-knockout (KO) mice after sham surgery and at 28 days after injury. n=4 to 6 for each group. Scale bar=50 μm. D, KLF4 mRNA expression levels in SMC-Cre and SMC-IRF4-KO carotid arteries and WT and SMC-IRF4-transgenic (TG) carotid arteries. n=3 per group at each time point. *P<0.05 vs the SMC-Cre group. #P<0.05 vs the WT group. E, KLF4 protein expression levels in the tissue samples of 2 independent groups. n=3 per group at each time point. *P<0.05 vs the SMC-Cre group. #P<0.05 vs the WT group. F, Relative enrichment of IRF4 binding at the indicated putative interferon-stimulating response elements on platelet-derived growth factor-BB (PDGF-BB) stimulation as determined by chromatin immunoprecipitation assay. mIL12-pro84 served as a positive control, and GAPDH served as a nonspecific control. n=5 per group. *P<0.05 vs the immunoglobulin G group. G, Infection of SMC-Cre, SMC-IRF4-KO, WT, and SMC-IRF4-TG primary mouse SMCs with an adenovirus carrying a KLF4 luciferase reporter. n=3 per group. *P<0.05 vs the SMC-Cre group. #P<0.05 vs the WT group. H, Relative KLF4 luciferase activity of mouse aorta vascular SMCs (MOVASs) transfected with AdIRF4, pKLF4-luciferase, and m-pKLF4-luciferase (IRF4 binding site deletion). *P<0.05 vs the pKLF4 group. #P<0.05 vs the pKLF4 with AdIRF4 group. I, Matrix metalloproteinase-2 (MMP2) mRNA expression levels in MOVASs infected with AdshRNA, AdshIRF4, or AdKLF4 after stimulation with PBS or PDGF-BB. *P<0.05 vs the AdshRNA-infected group. #P<0.05 vs the AdshIRF4-infected group. J, Proliferation of MOVASs infected with AdshRNA, AdshIRF4, or AdKLF4 after PDGF-BB stimulation as demonstrated by BrdU incorporation assays. *P<0.05 vs the AdshRNA-infected group. #P<0.05 vs the AdshIRF4-infected group. Data are expressed as mean±SD. Statistical comparisons were performed by 2-tailed Student t tests (B-G), 1-way ANOVA with Bonferroni posttest (H) or the Tamhane T2 posttest (J), or Kruskal-Wallis test followed by the Dunn test (I). IL-6 indicates interleukin-6; iNOS, inducible nitric oxide synthase; PCNA, proliferating cell nuclear antigen; PPARγ, peroxisome proliferator-activated receptor-γ; and TNF-α, tumor necrosis factor-α. SMC differentiation after vascular injury. We found that α-SMA expression was downregulated at 7 days after injury, reached its lowest level at 14 days after injury, and then approached baseline at 28 days after injury ( Figure  IB in the online-only Data Supplement), thus indicating that the post-wire injury changes in SMC differentiation were time dependent. We found that the expression levels of the differentiation markers α-SMA, SM22α, and Smoothelin were significantly higher in SMC-IRF4-KO mice than in control mice at both 14 and 28 days after injury and at 3 and 7 days, thus indicating that IRF4 ablation promotes SMC differentiation during neointima formation after wire injury ( Figure 7A and Figure XIVA in the online-only Data Supplement). Subsequent qPCR and Western blot analyses confirmed the changes in the expression levels of these SMC differentiation markers and indicated that the changes occurred at the mRNA and protein levels ( Figure 7B and 7C) . The expression levels of the above-mentioned SMC differentiation markers were significantly lower in SMC-IRF4-TG mice than in WT mice at both 14 and 28 days after injury; the same finding was observed through Western blotting, thus indicating that IRF4 overexpression inhibits SMC differentiation after wire injury ( Figure 7D and 7E). Consistent with this result, the qPCR and immunoblot results demonstrated that α-SMA, SM22α, and Smoothelin expression levels were downregulated in the primary SMCs of SMC-Cre, SMC-IRF4-KO, WT, and SMC-IRF4-TG mice compared with WT mice after PDGF-BB stimulation. Such downregulation was ameliorated by IRF4 ablation but potentiated by IRF4 overexpression ( Figure 7F and Figure XIVB in the online-only Data Supplement). Collectively, these data demonstrate that IRF4 promotes SMC dedifferentiation in addition to inhibiting SMC proliferation.
DISCUSSION
Neointima formation commonly occurs during atherosclerosis, arterial restenosis development, and vein bypass graft failure. 33 The molecular mechanisms underlying this complicated pathophysiological process remain to be elucidated. Here, we discovered the IRF4-KLF4 axis and elucidated its role in vasculoproliferative pathology. We postulate that the IRF4-KLF4 axis functions sequentially to protect arteries from injury ( Figure 8 ). In the exploration of the expression and effects of IRF4 and KLF4 in SMCs, we used α-SMA and SM22α as markers for the identification of SMCs. These 2 molecules have been reported to be expressed exclusively in adult SMCs and are recognized as the classic markers for the identification of differentiated SMCs in multiple publications, [41] [42] [43] [44] although both of them have been found to be expressed in non-SMCs under certain conditions. 42, 45 Moreover, the construction of SMC-specific KO or TG animal models depends on the SM22α promoter, which is widely used to construct SMC conditional KO or TG animals. [46] [47] [48] During vascular injury initiation, IRF4 expression in SMCs increases in response to injury and potentially exerts compensatory effects combating SMC proliferation and intimal hyperplasia in the acute injury phase. The upregulated IRF4 subsequently binds to an ISRE in the KLF4 gene promoter and promotes its expression, thereby maintaining SMC quiescence and preventing intimal hyperplasia development. When stimuli are excessive, IRF4 expression is downregulated significantly (similar to IRF4 ablation), thus leading to dramatic reductions in KLF4 expression and subsequent pathological neointima formation. Our results showed that KLF4 expression is enhanced and IRF4 expression is downregulated at 28 days after vascular injury, suggesting that KLF4 degradation is unsynchronized with IRF4 downregulation and lags behind the latter, and the potential mechanism needs to be investigated in our future study. However, RNA sequencing, qPCR, and Western blot analyses suggest that SMC-specific IRF4 ablation decreased KLF4 expression, whereas SMCspecific IRF4 overexpression increased its expression. More important, KLF4 overexpression was able to compensate for the intimal hyperplasia-promoting effect of IRF4 ablation, whereas KLF4 ablation abolished the in- timal hyperplasia-inhibiting effects of IRF4 overexpression. Our results strongly suggest that KLF4 is the key downstream effector molecule of IRF4 and mediates the protective effects of IRF4 in arteries. We observed that SMC proliferation and initiation of intimal hyperplasia occurred despite enhanced IRF4 expression at the early stages in the injury process (days 7 and 14) . This discrepancy suggests that the responsive increase of IRF4 expression is not sufficient to completely inhibit SMC proliferation and neointima formation at the start of the injury process. However, TG overexpression of IRF4 does have a protective effect on neointima formation beyond physiological elevation.
Therefore, the main mechanism by which IRF4 protects injured arteries involves KLF4. Originally identified as a negative regulator of cell growth in gut mucosa, 49 KLF4 has been documented to be an important transcriptional regulator of the proliferation of multiple cells. In colon cancer cells and fibroblasts, KLF4 inhibits DNA synthesis and cellular growth. 50, 51 KLF4 is upregulated in response to DNA damage and acts synergistically with P53 to promote transcriptional activation of the cyclin-dependent kinase inhibitor P21, thus leading to a cell-cycle arrest at the G1/S checkpoint. 52, 53 KLF4-induced P21 expression and cellular growth inhibition were also observed in cultured SMCs. 54 A subsequent study demonstrated that KLF4 promotes P21 expression by directly binding to the P21 promoter/enhancer in both cultured SMCs and injured carotid arteries; thus, KLF4 inhibits vascular injury-induced SMC proliferation and neointima formation. 35 A very recent study demonstrated that SMC-specific KLF4 ablation leads not only to reduced levels of SMC-derived mesenchymal stromal cells and macrophage-like cells but also to ameliorated atherogenesis. More than 800 genes, including genes regulating SMC proinflammatory responses, have been identified as KLF4 target genes. 34 Endothelial KLF4 is protective against atherothrombosis in mice. 55 These data demonstrate the importance of KLF4 in vascular pathology. 34 However, how the expression of this key SMC status regulator is regulated remains unclear. We determined that IRF4 is the critical transcriptional regulator of KLF4 expression. In our study, we did not observe significant differences in KLF4 expression between SMC-IRF4-KO and SMC-IRF4-TG mice without pathological injury stimuli, thus suggesting that the effect of the IRF4-KLF4 axis on neointima formation exerts its function mainly under stress conditions. By binding directly to the KLF4 gene promoter, IRF4 promotes KLF4 expression, which results in increases in P21 expression and inhibition of SMC proliferation and thus protects arteries from injury, findings supported by both in vitro and in vivo data. This mechanism is novel and differs from the mechanisms underlying the effects of IRF4 in hematopoietic malignancies, 27 ,28 metabolic diseases, 29, 30 cardiac hypertrophy, 11 and stroke. 19 The manner in which IRF4 inhibits the proliferation and migration of VSMCs and ameliorates neointima formation by directly regulating KLF4 expression further indicates that the mechanisms by which different IRFs affect neointima formation are distinct or even opposite, despite the similar molecular structures of different IRF family members. Particularly during neointima formation, IRF1 suppresses vascular remodeling by upregulating antiproliferative and proapoptotic genes such as the AT2 receptor, interleukinlβ-converting enzyme, and inducible nitric oxide synthase 25 ; IRF3 attenuates VSMC proliferation and suppresses neointima formation as a novel activator of peroxisome proliferator-activated receptor-γ 21 ; IRF7 promotes neointima formation and VSMC proliferation by interacting with ATF3 22 ; IRF8 modulates the phenotypic switching of VSMCs by regulating the activity of myocardin 24 ; and IRF9 increases VSMC proliferation and migration by decreasing SIRT1 deacetylase activity through binding to the ISRE in the SIRT1 promoter, thus subsequently accelerating neointima formation. 23 These findings provide important evidence of the flexibility, versatility, and potency of IRFs in regulating cardiometabolic diseases by engaging other critical downstream regulators. Moreover, these parallel studies extend the fundamental role of IRFs beyond innate immunity and strongly provide a basis for new and different therapeutic strategies for the management of arterial restenosis.
One surprising finding of this study was that IRF4 inhibits SMC proliferation and migration while promoting SMC dedifferentiation after vascular injury. This finding contrasts with the common concept that the proliferation of certain cells is inversely related to Figure 7 Continued. mRNA (B) and protein (C) expression levels in the carotid arteries of SMC-Cre and SMC-IRF4-KO mice after sham surgery or at 28 days after injury. n=3 per group. *P<0.05 vs the SMC-Cre group. D, α-SMA, SM22α, and Smoothelin (green) expression levels in both the neointima and media of wild-type (WT) and SMC-specific IRF4-transgenic (TG) (SMC-IRF4-TG) mice at 14 and 28 days after injury as determined via immunofluorescence staining. The IOD values of α-SMA, SM22α, and Smoothelin immunostaining were calculated (n=5-7 at 14 days, n=4-6 at 28 days). Scale bar=50 μm. *P<0.05 vs the WT group. E, α-SMA, SM22α, and Smoothelin protein expression levels in the carotid arteries of WT and SMC-IRF4-TG mice after sham surgery or at 28 days after injury. n=3 per group. *P<0.05 vs the WT group. F, α-SMA, SM22α, and Smoothelin mRNA expression levels in the primary SMCs of SMC-Cre, SMC-IRF4-KO, WT, and SMC-IRF4-TG mice immediately after platelet-derived growth factor-BB stimulation or 24 or 48 hours later. n=3 per group. *P<0.05 vs the SMC-Cre group. #P<0.05 vs the WT group. Data are expressed as mean±SD. Statistical comparisons were performed by 2-tailed Student t tests. Our present study elucidated the role of the interferon regulatory factor 4 (IRF4)-Krüppel-like factor 4 (KLF4) axis in modulating neointima formation. IRF4 is localized primarily in smooth muscle cells (SMCs) and is eventually downregulated after arterial injury. IRF4 increases KLF4 expression by directly binding to the interferon-stimulating response element (ISRE) regions of the KLF4 promoter and subsequently moderating the expression levels of the downstream effectors of KLF4. IRF4 enhances P21 expression and suppresses SMC differentiation marker and matrix metalloproteinase-2 (MMP2) expression through KLF4. Because the suppressive effect of IRF4 on SMC proliferation and migration is more dominant than its promoting effect on SMC phenotypic switching, its overexpression ultimately inhibits neointima formation. VSMCs indicates vascular smooth muscle cells. their differentiation. SMC proliferation and migration are the most important events in neointima formation. 33 After arterial injury, the levels of endotheliumderived growth-inhibiting factors such as nitric oxide 56 and prostacyclin 57 are reduced because of endothelial damage. These alterations are usually accompanied by platelet activation. 58 In addition, the production of growth-promoting factors (such as PDGF) by activated platelets, leukocytes, and SMCs is increased after arterial injury. These changes in the microenvironment induce corresponding changes in gene expression in SMCs. 59 Here, we observed that IRF4 expression changes at the transcriptional level in a time-dependent manner. Specifically, IRF4 expression is initially upregulated after injury but is subsequently downregulated, suggesting that IRF4 is involved in the development of arterial restenosis. Alterations in the SMC gene expression profile prime the phenotypic switching of these cells from a quiescent contractile state to an active proliferative state, 42, 60 during which their repertoire of contractile proteins (α-SMA, SM22α, and Smoothelin) is markedly downregulated, whereas the expression of genes related to proliferation (PCNA and CyclinD1), migration (MMPs), and extracellular matrix production in SMCs is upregulated. 42, 61 These serial alterations facilitate SMC migration and proliferation and promote neointima formation and arterial restenosis development. Our findings on the paradoxical dual function of IRF4 (inhibiting SMC proliferation and migration while promoting SMC dedifferentiation) after vascular injury suggest that IRF4 plays a novel role in regulating SMC status. This divergent SMC behavior has been documented in previous studies. 42 SMCs can proliferate very rapidly while expressing increased levels of differentiation markers during late embryogenesis and postnatal development. 62 In response to injury, KLF4 can inhibit SMC differentiation but also suppresses SMC proliferation. 35 An in vitro study has demonstrated that the PDGF-BB-stimulated reduction in SMC differentiation marker expression is independent of the effects of PDGF-BB on mitogenesis. 63 Collectively, the results obtained by different laboratories suggest that SMC growth and differentiation can be synchronized, particularly when SMCs are exposed to injury-related stimuli. In the present study, the results pertaining to both our IRF4 ablation and IRF4 overexpression models clearly indicate that the overall function of IRF4 in arterial injury is to inhibit neointima formation, suggesting that the inhibitory effects of IRF4 on SMC proliferation and migration outweigh its promoting effects on SMC dedifferentiation in response to injury. Furthermore, we observed that a small portion of IRF4 expression was located in macrophages, and previous studies have demonstrated that IRF4 promotes the switching of differentiated macrophages to M2 macrophages 29, 64, 65 ; this switching has been demonstrated to play a beneficial role in suppressing neointima formation. Therefore, the effect of IRF4 on macrophage polarization may provide an additive effect on the function of IRF4 in VSMCs in neointima formation that was identified herein. This requires further investigation.
Conclusions
Our findings demonstrate that the key innate immune regulator IRF4 protects arteries against neointima formation by directly regulating the expression of KLF4, a well-known central regulator of SMC phenotypic switching. The protective effects of IRF4 against neointima formation primarily involve its inhibition of KLF4-dependent SMC proliferation and migration. Our study not only elucidated a key mechanism underlying neointima formation but also shed more light on how innate immune signaling in nonimmune cells affects cardiometabolic disease development. The IRF4-KLF4 axis may be a promising potent therapeutic target for the treatment of restenosis.
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